Moderna Projects More Growth Outside US After FDA Rejects Influenza Vaccine

About 50 percent of revenue in 2026 is expected to come from outside the United States, compared to 38 percent in 2025, said executives.

Moderna CEO Stephane Bancel in Washington on April 18, 2024. Saul Loeb/AFP via Getty Images

Moderna executives on Feb. 13 said the company forecasts more growth outside the United States after the U.S. Food and Drug Administration declined to review Moderna’s application for its experimental vaccine against influenza.

About 50 percent of revenue in 2026 is expected to come from outside the United States, compared to 38 percent in 2025, Moderna executives said in an earnings call.